Today's News and Commentary

Read today’s Kaiser Health News

In other news:

Supreme Court upholds Affordable Care Act’s preventive care mandate: The Supreme Court on Friday upheld a portion of the Affordable Care Act that requires health plans to provide free preventive care such as screenings for cancer and HIV.
In a 6-3 decision, the justices ruled against a Christian-owned business and individuals who objected to being forced to offer medications intended to prevent the spread of HIV among people at risk. The plaintiffs contend the pre-exposure prophylaxis (PrEP) treatment administered to prevent infections, “encourage and facilitate homosexual behavior” in conflict with their religious beliefs.

The Advisory Committee on Immunization Practices—Legal Roles, Challenges, and Guardrails An excellent review. For example: What stops the DHHS secretary from simply disbanding the ACIP and replacing its recommendations with his own? Typically, disbanding an agency-created advisory committee would be within the authority of that agency’s leadership. But a decision to dissolve the ACIP would be complicated by the fact that Congress has repeatedly and explicitly assigned it statutory roles. 

Republicans are dealt a setback on their big bill as Senate referee disqualifies key provisions: Senate parliamentarian Elizabeth MacDonough, who adjudicates procedural disputes between the two parties, has disqualified several provisions, including Medicaid rules prohibiting funds without verification of immigration status, reimbursement changes to contracts with pharmacy benefit managers (PBMs), provider tax restrictions aimed at saving federal dollars, and new limitations surrounding eligibility for Affordable Care Act funding.
The disqualified provisions total from $200 billion to $300 billion in savings over a decade, said Matthew Fiedler, an expert in health care policy and economics at the Brookings Institution.  

About health insurance/insurers

What 8 recent studies found about Medicare Advantage Great summary

Different Data Source, But Same Results: Most Adults Subject to Medicaid Work Requirements Are Working or Face Barriers to Work See Fig.1 for a summary.

Medicare Advantage Plan Disenrollment: Beneficiaries Cite Access, Cost, And Quality Among Reasons For Leaving: Enrollees’ self-reported inability to access and receive high-quality care, more than perceived burdens of out-of-pocket costs, was associated with MA plan disenrollment, as was an objective measure of plan generosity. Difficulty accessing needed medical care was more strongly associated with MA-to–traditional Medicare exits than MA-to-MA plan switching. Dissatisfaction with access, cost, and quality was much more common for enrollees in poor health. These findings renew concerns about access to high-quality care for high-risk and other MA enrollees. 

How Likely Are You to Have an Extended Long-Term Care Need?: Data on long-term-care usage suggests that the majority of people will need long-term care in their lifetimes. A research brief from the Department of Health and Human Services estimates that 56% of Americans turning 65 are likely to develop a condition requiring long-term care. Other studies have pegged the lifetime risk of needing long-term care as high as 70%.

About hospitals and healthcare systems

2025 Impact of Change Forecast From sG2: 2025 Impact of Change Forecast Key Takeaways
The 2025 Impact of Change Forecast provides 10-year projections for anticipated shifts in sites of care delivery across the nation, including:
 Outpatient (OP) care patient volumes projected to grow 18%
 Inpatient (IP) care patient discharges to grow 5%
 Pediatric OP volume growth forecasted at 8%
 Cancer OP volumes expected to grow 18%, while IP remains flat
 GLP-1s will contribute to slowing growth in IP discharges for type 2 diabetes patients to 8%
 Post-Acute Care to grow 31% 

About the public’s health

4 in 5 Americans support childhood vaccine requirements, poll finds: A poll released today shows that 79% of US adults support requiring children to be vaccinated against preventable infectious diseases like measles, mumps, and rubella to attend school, with even two thirds of Republicans and those who support the "Make America Great Again" (MAGA) movement agreeing with such measures.
The poll of 2,509 adults, conducted by the Harvard T.H. Chan School of Public Health and the de Beaumont Foundation, also found that, among the 21% who don't support school vaccine mandates, their reasoning focused more on parental choice than on safety concerns.

Vaccine experts reject new RFK Jr.-backed federal panel, urge use of past guidance: The Infectious Disease Society of America is telling its members they should use the vaccination schedule recommended by the previous iteration of the U.S. Centers for Disease Control and Prevention's vaccine advisory council because the new federal advisory group's recommendations "can't be trusted," according to the group's president, a Northwestern Medicine immunization expert.
IDSA President Dr. Tina Tan said this afternoon she expects a coalition of health care groups including her organization, the American Academy of Pediatrics and the American Medical Association would soon provide further guidance, likely later on this summer, on what vaccines should be administered and at what doses. 

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

National Health Expenditure Projections, 2024–33: Despite Insurance Coverage Declines, Health To Grow As Share Of GDP: READ THE ENTIRE ARTICLE. Below is the abstract:
National health expenditures are projected to have grown 8.2 percent in 2024 and to increase 7.1 percent in 2025, reflecting continued strong growth in the use of health care services and goods. During the period 2026–27, health spending growth is expected to average 5.6 percent, partly because of a decrease in the share of the population with health insurance (related to the expiration of temporarily enhanced Marketplace premium tax credits in the Inflation Reduction Act of 2022) and partly because of an anticipated slowdown in utilization growth from recent highs. Each year for the full 2024–33 projection period, national health care expenditure growth (averaging 5.8 percent) is expected to outpace that for the gross domestic product (GDP; averaging 4.3 percent) and to result in a health share of GDP that reaches 20.3 percent by 2033 (up from 17.6 percent in 2023).[Emphasis added]

Supreme Court allows states to cut off Medicaid funding for Planned Parenthood: A divided Supreme Court on Thursday ruled against Planned Parenthood, saying Medicaid patients do not have a right to sue to obtain non-abortion health care from the organization’s medical providers.
The decision allows South Carolina to cut off Medicaid funding for Planned Parenthood. It also has implications for patients in other states at a time when Republicans in Congress and the Trump administration are separately trying to defund even non-abortion health care offered by the nation’s largest abortion provider.

 RFK Jr. says U.S. will stop funding global vaccine alliance Gavi: The United States will halt its contributions to Gavi, the global alliance that works to expand access to vaccines for children in some of the world’s poorest countries, Health and Human Services Secretary Robert F. Kennedy Jr. said Wednesdaya move that public health experts said would have deadly consequences.

Healthcare’s broken math: 11 signs the numbers don’t add up A really good overview of some major issues. 

About health insurance/insurers

Delays and Denials in Medicare Advantage Fixing the Systemic Conflict of Interest An interesting proposal create a medical necessity review function for Medicare Administrative Contractors.

Healthcare billing fraud: 10 recent cases FYI

About hospitals and healthcare systems

How supply costs have grown at 20 health systems: On average, supply costs accounted for 13% of a hospitals’ expenses in 2024, according to the American Hospital Association’s annual “Cost of Caring” report released April 30. 
In 2024, total hospital expenses grew 5.1%, outpacing the overall inflation rate of 2.9% according to the report. 

About pharma

Déjà vu for Bristol Myers as it faces another anti-competition lawsuit over blockbuster Pomalyst The specific case is not as important as it includes examples of many different mechanisms companies have used to extend their patents.

Walgreens beats Wall Street expectations ahead of sale to Sycamore Partners: Walgreens Boots Alliance reported adjusted earnings per share of 38 cents for the third quarter of its 2025 fiscal year, which beat Zacks Investment Research's estimate of 34 cents per share. Zacks noted this was an 11.76% "earnings surprise" and said the company has, in the last four quarters, surpassed consensus earnings per share estimates four times. 

‘It’s heartbreaking’: Bad cancer drugs shipped to more than 100 countries: Vital chemotherapy drugs used around the world have failed quality tests, leaving cancer patients in more than 100 countries at risk of ineffective treatments and potentially fatal side effects, the Bureau of Investigative Journalism (TBIJ) can reveal.
The drugs in question form the backbone of treatment plans for numerous common cancers including breast, ovarian and leukemia. Some drugs contained so little of their key ingredient that pharmacists said giving them to patients would be as good as doing nothing. Other drugs, containing too much active ingredient, put patients at risk of severe organ damage or even death.

About the public’s health

Kennedy remake of CDC vaccine panel has US insurers reassessing sources of expertise: Health insurers are considering new expert sources to help determine which vaccines to pay for as anti-vaccine activist and now U.S. Health Secretary Robert F. Kennedy Jr. begins to revise government recommendations for inoculations, according to multiple insurance industry insiders and experts.

CDC advisory panel, selected by RFK Jr., recommends thimerosal be dropped from flu vaccines The preservative is only in a couple versions of flu vaccine and limited to multi dose vials. This action was really a vanity project for RFK Jr since thimerosal is safe and was long ago eliminated from childhood vaccines. Amazing, from a scientific view, that the committee wasted time on this issue.

PFAS could be replaced with safe graphene oxide solution: Northwestern University researchers have developed a new water- and oil-resistant material that could become a safe, viable replacement for harmful plastics and toxic per- and polyfluoroalkyl substances (PFAS) in food packaging.
Derived from graphene oxide, the material is non-toxic, environmentally friendly and affordable. 

About healthcare IT

Optum launches AI marketplace: Optum has launched a new AI marketplace aimed at helping healthcare organizations more easily adopt AI tools.
The platform connects healthcare providers, payers and developers with curated AI products designed for clinical and administrative use, according to a June 25 news release from Optum. According to the company, the marketplace offers ready-to-use solutions and APIs that can be quickly integrated, helping organizations avoid the time and expense of building tools from scratch.The platform includes AI-powered products from Optum as well as other technology companies like ServiceNow, Microsoft and Google. 

Oversight Beyond the FDA: New Report Untangles the Complex Regulation of Health AI Tools: – A new report from the Bipartisan Policy Center (BPC) examines the complex and often fragmented regulatory landscape for health AI tools that fall outside the jurisdiction of the U.S. Food and Drug Administration (FDA).

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

NIH halts grant terminations ‘effective immediately,’ email says: Days after a federal judge ordered the restoration of more than 1,000 biomedical research grants, the National Institutes of Health is halting further terminations of grants, an internal email shows. 

Since President Trump’s inauguration in January, the nation’s largest biomedical research funder has terminated an unprecedented number of research grants. The email obtained by STAT does not state the reason for the decision, but it came a week after a federal judge in Boston ruled that some of the terminations were “void and illegal” — and just hours after the judge refused the administration’s request to pause his order. 

About health insurance/insurers
ACA marketplace enrollment could shrink by half : Marketplace enrollment could decline between 47% and 57% if premium tax credits expire and proposed changes in Congress become law, according to an analysis from Wakely, a healthcare market research firm .   

About pharma

BREAKING: CVS PBM Hit With $95M Judgment For Overbilling Medicare A Pennsylvania judicial decision.

About healthcare IT

Federal court says copyrighted books are fair use for AI training: A federal judge this week ruled that artificial intelligence company Anthropic did not break the law when it used copyrighted books to train its chatbot, Claude, without the consent of the texts’ authors or publishers — but he ordered the company to go to trial for allegedly using pirated versions of the books. 

About healthcare personnel

Gender Differences in Primary Care Physician Earnings and Outcomes Under Medicare Advantage Value-Based Payment: In this cohort study, women PCPs in value-based payment models had equal or better quality outcomes and higher value-based earnings compared to men in their practice groups. These results substantiate prior evidence that women physicians perform better on process and outcome measures, yet receive incommensurate patient ratings.The reversal of the gender gap under value-based payment is likely due to fewer emergency department visits and hospitalizations among women PCPs’ patients and may in turn reflect better alignment of value-based models to practice patterns more common in women (eg, more face-to-face time per visit). Equal pay could carry benefits beyond fair compensation, including reduced burnout and improved retention of the increasingly female primary care workforce to care for the aging US population. 

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

About Covid-19

WHO TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: NB.1.8.1: NB.1.8.1 has been designated a SARS-CoV-2 variant under monitoring (VUM) with increasing proportions globally, while LP.8.1 is starting to decline. Considering the available evidence, the additional public health risk posed by NB.1.8.1 is evaluated as low at the global level. Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease. Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation. 

About health insurance/insurers

Medicaid Work Requirements Have Mostly Failed. The GOP Is Still Pushing Them.:Trump’s tax-and-spending bill aims to require many Americans to work to collect Medicaid. Similar efforts in Georgia and Arkansas have largely fallen flat. 

  

Today's News and Commentary

Read today’s Kaiser Health News

About pharma

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%: Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. 
Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S. 
But Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" and accused the telehealth company of "deceptive" marketing that is putting patient safety at risk. 

The 25 most expensive hospital drugs FYI

10 drug shortages causing the greatest strain in hospitals: Vizient FYI

About the public’s health

What the Texas food label law means for the rest of America: The first-of-its-kind legislation requires labels on foods containing 44 dyes or additives commonly found in the country’s food supply, such as in baked goods, candy and drinks. The new mandate will set off a scramble within the food industry, which must decide whether to reformulate its products to avoid warning labels, add the newly mandated language, stop selling certain products in Texas or file lawsuits against the measure.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

NIH grant funding losses, by state FYI 

About pharma

How we plan to cut FDA drug approval time by months [From the FDA commissioner]:The program will make use of the idle time during clinical trials — time needed to see how the drug in question performs. Instead of submitting all the data at the end of a trial, qualifying manufacturers will be able to submit most elements of the application — including manufacturing details and drug labeling — while the trial is underway. The FDA will be able to review the early data and resolve any issues with the manufacturer at that time. Once the trial concludes, final data will be submitted. Then there will be about one month of FDA review, followed by a focused, one-day meeting with FDA scientists to reach a decision. This split-submission approach is entirely feasible — as shown by its success during Operation Warp Speed at the start of the covid-19 pandemic.

Comment: Great news and makes sense. But how will the FDA review data if it fires seasoned staff? See the article below.

FDA gene therapy leaders sidelined amid broader agency overhaul: The FDA has placed Nicole Verdun, director of the Office of Therapeutic Products (OTP), and her deputy Rachel Anatol on administrative leave, removing two senior officials that industry leaders said have steered efforts to modernise the agency's approach to cell and gene therapy regulation over the past two years.
The personnel moves represent the latest in a series of changes across the Department of Health and Human Services (HHS) since the Trump administration took office in January. The FDA specifically has experienced significant turnover among senior staff, including the ousting of long-time Center for Biologics Evaluation and Research (CBER) director Peter Marks in March. He has since been succeeded by Vinay Prasad.

NICE reaffirms negative stance on Alzheimer's therapies Kisunla, Leqembi: The UK's National Institute for Health and Care Excellence (NICE) has again ruled that the benefits offered by two recently approved amyloid plaque-targeting therapies for Alzheimer's disease are too small to justify their additional cost to the NHS.  

About the public’s health

Weight Trajectory Impacts Risk for Ten Distinct Cardiometabolic Diseases: Results: Compared to weight stability, weight cycling associated with almost 30% increased risk for obstructive sleep apnea (HR 1.28; 95% CI 1.15-1.42), MASLD (HR 1.28; 95% CI 1.08-1.51), and T2DM (HR 1.23; 95% CI 1.10-1.38). Weight cycling also associated with more than 50% increased risk for heart failure (HR 1.54; 95% CI 1.31-1.82), although both weight gain and weight loss also showed increased risk for HF (HR 1.29; 95% CI 1.08-1.55 and HR 1.32; 95% CI 1.10-1.58, respectively).
Conclusions: The relationship between weight cycling and cardiometabolic disease risk was independent of having high baseline BMI, which was similar among weight trajectory groups. The present findings support promoting either weight stability at high BMI or weight loss if able to be maintained to prevent the incidence of a variety of cardiometabolic diseases. 

About healthcare IT

Billions of login credentials have been leaked online, Cybernews researchers say: Researchers at cybersecurity outlet Cybernews say that billions of login credentials have been leaked and compiled into datasets online, giving criminals “unprecedented access” to accounts consumers use each day.
According to a report published this week, Cybernews researchers have recently discovered 30 exposed datasets that each contain a vast amount of login information — amounting to a total of 16 billion compromised credentials. That includes user passwords for a range of popular platforms including Google, Facebook and Apple.
Sixteen billion is roughly double the amount of people on Earth today, signaling that impacted consumers may have had credentials for more than one account leaked.

Health systems caught in data breach affecting 5.4 million individuals: Episource, which provides medical coding and risk adjustment services to health systems and payers, said it turned off its computer systems Feb. 6 after detecting unusual activity on its network. The firm later determined that a cybercriminal accessed and stole data between Jan. 27 and Feb. 6.
The data may have included names, dates of birth, Social Security numbers, diagnoses, medications and treatment information. Episource said it has no evidence any of the data has been misused. 

About healthcare personnel

17 systems launching physician residency programs FYI

Today's News and Commentary

No Kaiser Health News because of the Juneteenth holiday.

About health insurance/insurers

Growth Trends for ICHRA & QSEHRA [ICHRA: Individual Coverage Health Reimbursement Arrangement for employers of all sizes QSEHRA: Qualified Small Employer HRA for fewer than 50 employees]: Small employer ICHRA adoption is up 52% 2024-2025 among Founding Members. Aggregated ALE [Applicable Large Employer], an employer with 50 or greater full-time employees adoption is up 34% 2024-2025, with some cohorts showing 49% year-over-year growth.
Comment: Scan the charts to see how these plans are growing.

Is Price Transparency Helping? OUR FINDINGS REVEALED
—Significant price convergence, with:
High rates declining by 6.3% annually
Low rates increasing by 3.4% annually
—Pervasive price convergence across 83% of the markets we examined
—Greater price convergence in outpatient services compared to inpatient services 
Comment: Price transparency was meant to help individuals shop for services, However, this analysis examined commercially negotiated rates, i.e., institutional payers used the transparency to negotiated better rates. While this change helps individuals with respect to premiums, it does not help them with out of pocket expenses (unless the payers negotiate on their behalf).

About hospitals and healthcare systems

26 health systems dropping Medicare Advantage plans FYI 

About pharma

FDA to tighten up on use of American patients' biological material in "hostile countries": Less than two weeks after meeting with experts to discuss ways to help speed the development of cell and gene therapies, the FDA is moving to impose stricter oversight on clinical trials that involve exporting Americans' living cells outside the country for genetic engineering. The agency singled out destinations such as China and other "hostile countries," amid concerns that the international transfer and manipulation of the biological material may have exposed sensitive genetic data to "misuse" by foreign governments.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:
2025 Scorecard on State Health System Performance From the Commonwealth Fund:
Scorecard Highlights

  • Topping the 2025 Scorecard’s overall health system rankings are Massachusetts, Hawaii, New Hampshire, Rhode Island, and the District of Columbia, based on 50 measures of health care access and affordability, prevention and treatment, avoidable hospital use and costs, health outcomes and healthy behaviors, income disparity, and equity.

  • The lowest-ranked states are Mississippi, Texas, Oklahoma, Arkansas, and West Virginia.

  • Uninsured rates fell to record lows in all states by 2023, and differences in health coverage and access to care narrowed between states. These improvements were in all likelihood due to the Affordable Care Act’s coverage expansions, recent state expansions of Medicaid eligibility, and more affordable marketplace plan premiums.

  • The number of children receiving all doses of seven recommended early childhood vaccines fell in most states between 2019 and 2023. In five states, including Nebraska and Minnesota, the decline exceeded 10 percent.

  • The infant mortality rate (deaths within the first year of life) worsened in 20 states between 2018 and 2022, with considerable variation across states.

  • Premature, avoidable deaths vary considerably across states — the rate in West Virginia is more than twice as high as the rate in Massachusetts. Not only are avoidable mortality rates higher in the United States than in other high-income countries, but they are also on the rise, even as they fall elsewhere. .

  • Wide racial disparities in premature deaths are the norm in most states. In 42 states and D.C., avoidable mortality for Black people is at least two times the rate for the group with the lowest rate.

  • When it comes to having affordable health coverage, good-quality care, and the opportunity to live a healthy life, where you live matters in the U.S. Targeted, coordinated federal and state policies are needed to raise health system performance across the nation. 

About health insurance/insurers

US Health, Non-Life Personal Line Insurers’ Sector Outlooks Lowered: Fitch Ratings has lowered the outlook for the U.S. Health Insurance sector to ‘deteriorating’ from ‘neutral’ and the U.S. non-life personal line sector outlook to ‘neutral’ from ‘improving’. The outlooks for other insurance sub-sectors remain ‘neutral’.
The outlook change for U.S. health insurers reflects ongoing higher growth in healthcare utilization and increasing crystallization around the form and magnitude of cuts to government-funded healthcare programs, primarily Medicaid, incorporated into the ‘One Big Beautiful Bill Act’. The bill was passed by the House of Representatives on May 22 and is currently with the Senate, where potential changes could either mitigate or exacerbate its impact on the Medicaid program. 

About hospitals and healthcare systems

National Hospital Flash Report: Key Takeaways

1. Hospital financial performance improved between January and April. On a year-to-date basis, hospital performance in the first four months of 2025 compared favorably to the same time period in 2024.
2. Average length of stay decreased and adjusted discharges per calendar day increased compared to the prior year period. This reflects improved patient throughput and a higher demand for hospital services.
3. Measures of patient volume showed improvement. Inpatient revenue, discharges, ED visits and operating room minutes all increased compared to the prior year period.

Ascension Enters into an Agreement to Acquire AMSURG: This transformative acquisition will add more than 250 ambulatory surgery centers across 34 states to Ascension’s network, significantly expanding its ability to deliver care in community-based settings, upon closing of the transaction.   

About pharma

HIV protection with just two shots a year: FDA approves Gilead drug: The Food and Drug Administration approved Wednesday a powerful new drug that provides nearly complete protection against HIV infection with just a single administration every six months.
The injection, known chemically as lenacapavir and to be marketed as Yeztugo, has been hailed as the closest thing the field has ever had to a vaccine — a groundbreaking intervention that, if rolled out properly, could bring a 45-year-old pandemic to heel. Drugs to prevent HIV, called PrEP, have been around for a decade, but they generally require taking a daily pill and have not substantially curbed global infections. 

About healthcare personnel

Clinician Workforce Insights Report See, particularly, page 6 fora list of specialty shortages and surpluses.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

KFF Health Tracking Poll: Views of the One Big Beautiful Bill Well worth reading. The “bottom line” is: The “One Big Beautiful Bill Act”…is viewed unfavorably by a majority of adults (64%), including large majorities of independents and Democrats.

‘Extremely disturbing and unethical’: new rules allow VA doctors to refuse to treat Democrats, unmarried veterans: Doctors at Department of Veterans Affairs (VA) hospitals nationwide could refuse to treat unmarried veterans and Democrats under new hospital guidelines imposed following an executive order by Donald Trump.
The new rules, obtained by the Guardian, also apply to psychologists, dentists and a host of other occupations. They have already gone into effect in at least some VA medical centers.
Medical staff are still required to treat veterans regardless of race, color, religion and sex, and all veterans remain entitled to treatment. But individual workers are now free to decline to care for patients based on personal characteristics not explicitly prohibited by federal law.
Language requiring healthcare professionals to care for veterans regardless of their politics and marital status has been explicitly eliminated.
Doctors and other medical staff can also be barred from working at VA hospitals based on their marital status, political party affiliation or union activity, documents reviewed by the Guardian show…
In making the changes, VA officials cite the president’s 30 January executive order titled “Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government”…
In an emailed response to questions, the VA press secretary, Peter Kasperowicz, did not dispute that the new rules allowed doctors to refuse to treat veteran patients based on their beliefs or that physicians could be dismissed based on their marital status or political affiliation, but said “all eligible veterans will always be welcome at VA and will always receive the benefits and services they’ve earned under the law”.
He said the rule changes were nothing more than “a formality”, but confirmed that they were made to comply with Trump’s executive order. Kasperowicz also said the revisions were necessary to “ensure VA policy comports with federal law”. He did not say which federal law or laws required these changes.

70% of US medical devices are only available overseas, report finds: As hospital executives and healthcare organizations express concern about how tariffs may affect the medical supply chain, a recent industry analysis found that about 70% of medical devices marketed in the U.S. are manufactured solely overseas. 
GlobalData, which tracks the medical device supply chain, reported that while 75% of U.S.-marketed medical devices are produced internationally, 69% of those are only available through foreign manufacturers. 
About 13% of the overseas-manufactured devices originate from China. On June 11, President Donald Trump stated that the total tariffs on products made in China stand at 55%.

Projected Effects of Proposed Cuts in Federal Medicaid Expenditures on Medicaid Enrollment, Uninsurance, Health Care, and Health: Enactment of the House bill advanced in May would increase the number of uninsured persons by 7.6 million and the number of deaths by 16 642 annually, according to a mid-range estimate.  

About health insurance/insurers

Physicians’ prior auth burden: 10 stats An informative summary of this issue.

About pharma

FDA's new speedy review programme will be open only to US drugmakers: The FDA on Tuesday announced a voucher system that promises to review drug and biologic marketing applications within one to two months. The catch? Only drug developers based in the US, and are "aligned with US national priorities," are eligible.
"So who can get a national priority voucher? The key is in the name," FDA Commissioner Marty Makary said in a video posted to X. "The programme will support US drug developers who are addressing our most important US national priorities."
The national priorities listed by the agency cover four broad health buckets. Companies must be working to address a US health crisis; developing an innovative treatment; addressing an unmet public health need, such as by supporting pandemic preparedness; or increasing US national security, including by upping domestic manufacturing. 

Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion: Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient getting dosed in a Phase 3 trial of Verve’s lead candidate. In total, Lilly could pay up to $1.3 billion.

All states, territories agree to $7.4B Purdue Pharma opioid settlement: The attorneys general of all 50 states, Washington D.C., and four territories have agreed to sign on to a $7.4 billion settlement with Purdue Pharma and the members of the Sackler family who own the company. 
The settlement seeks to resolve thousands of lawsuits over the opioid crisis. The family members would acknowledge their role in contributing to the epidemic with rampant production and aggressive marketing of opioids for decades.  

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

Judge deems Trump's National Institutes of Health grant cuts illegal: A federal judge in Boston on Monday said the termination of National Institutes of Health grants for research on diversity-related topics by President Donald Trump's administration's was "void and illegal," and accused the government of discriminating against minorities and LGBT people.
U.S. District Judge William Young during a non-jury trial said NIH violated federal law by arbitrarily canceling more than $1 billion in research grants because of their perceived connection to diversity, equity and inclusion initiatives.
Young said he was reinstating grants that had been awarded to organizations and Democratic-led states that sued over the terminations. And the judge strongly suggested that as the case proceeds he could issue a more sweeping decision.

8 healthcare startups make CNBC Disruptor 50 list FYI: Eight startups that specialize in healthcare made the 2025 CNBC Disruptor 50 list. 

Average age of moms giving birth in U.S. has climbed to nearly 30 years old, CDC data show: In the report, published Friday by the CDC's National Center for Health Statistics, researchers found the average age of all mothers giving birth in the United States increased from 28.7 years old in 2016 to 29.6 in 2023. For new first-time moms, average age also increased, from 26.6 in 2016 to 27.5 in 2023. The data was taken from the National Vital Statistics System, which includes all birth records in the country. 

Former 23andMe CEO wins bidding war against Regeneron: The genetic testing firm announced Friday that, after hearing bids from both Wojcicki's TTAM Research Institute non-profit and Regeneron Pharmaceuticals — again — she made the winning offer. TTAM will spend $305 million to acquire all of 23andMe's assets, including the Personal Genome Service and Research Services, as well as the Lemonaid Health business.

About Covid-19

New COVID variant NB.1.8.1 could be more than 1 in 3 cases, CDC projects: The new COVID-19 variant NB.1.8.1, which was linked to a large surge of hospitalizations in parts of Asia, could now make up more than 1 in 3 cases across the United States, the Centers for Disease Control and Prevention projected this week. 

Cost-Utility Analysis of COVID-19 Vaccination Strategies for Endemic SARS-CoV-2: In this model-based economic evaluation of 1 million simulated individuals, annual vaccination of adults aged 65 years and older was estimated to be a cost-effective intervention, while the cost effectiveness of vaccination for younger ages and biannual vaccination for older adults was dependent on model assumptions.

Changed Recommendations for COVID-19 Vaccines for Children and Pregnant Women: A Failure of Process, Policy, and Science Excellent summary.

About health insurance/insurers

Medicare and the Health Care Delivery System MedPAC’s annual June analysis and recommendations provides a wealth of information and reasoned suggestions for changes.

Proposed Medicaid cuts, quantified  An excellent summary of what would happen if the House legislation passes the Senate.

How Congress members get their health insurance: Members of Congress and their staff receive their insurance through DC Health Link, the exchange market in Washington, D.C. The arrangement was implemented in 2014, as part of the ACA, which established the marketplace. 
In addition to federal benefits, many members of Congress are also eligible for Medicare. In 2025, a third of senators and about 20% of representatives were over the age of 70, according to Pew Research Center.

6 payers recently fined by states FYI

About pharma

15 largest pharmacies in the US FYI: Total prescription dispensing revenue at U.S. retail pharmacies hit $683 billion in 2024, marking a 9% increase from the previous year, according to a June 16 post from the Drug Channels Institute. 

AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech: The drugmaker will collaborate with CSPC Pharmaceuticals on several drugs including a pill to treat immunological diseases. CSPC will receive $110mn upfront and will be eligible for payments based on development milestones of up to $1.6bn and sales milestones of up to $3.6bn. 

About healthcare IT

Multinational Attitudes Toward AI in Health Care and Diagnostics Among Hospital Patients:
Findings  This cross-sectional study surveying 13 806 patients using a nonprobability sample from 74 hospitals in 43 countries found that while patients were generally supportive of AI-enabled health care facilities and recognized the potential of AI, they preferred explainable AI systems and physician-led decision-making. In addition, attitudes varied significantly by sociodemographic characteristics.
Meaning  These findings highlight the global imperative for health care AI stakeholders to tailor AI implementation to the unique characteristics of individual patients and local populations and provide guidance on how to optimize patient-centered AI adoption.

Today's News and Commentary

HealthcareInsights will resume on Monday, June 16.

Read today’s Kaiser Health News

In other news:

NIH restores DEI prohibition for grant recipients within hours of rescinding it: On Monday, the National Institutes of Health rescinded a 7-week-old DEI directive, only to reinstate it hours later without explanation.
The maneuvering dates back to April, when the National Institutes of Health began requiring grantees to certify they did not have diversity, equity, and inclusion policies that ran afoul of anti-discrimination laws or boycotts of Israel in order to receive funding for research. The move made some universities worry about their ability to accept grant funding from the NIH without opening themselves up to litigation from the Trump administration. 

Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent: Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks the court’s approval to buy the struggling firm.
Biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person’s express, informed consent, Oregon Attorney General Dan Rayfield said in a news release about the lawsuit. Customers should have the right to control such deeply personal information and it cannot be sold like ordinary property, it said.  

About health insurance/insurers

Moody’s downgrades UnitedHealth’s outlook to negative, affirms credit ratings: Moody’s Ratings has downgraded UnitedHealth Group’s outlook from stable to negative, citing “a number of adverse trends simultaneously.” 
The ratings agency also affirmed the company’s strong credit ratings, including its long-term issuer and senior unsecured debt ratings, as well as its short-term commercial paper rating. UnitedHealthcare’s financial strength rating was maintained as well.
Moody’s downgraded UnitedHealth because of the higher than expected medical cost trend within its Medicare Advantage business, increased leverage post-cyberattack on Change Healthcare, a decline in the company’s risk-based capital level, reduced interest coverage, and potential credit risk from reported Justice Department investigations into its MA billing practices. 

About hospitals and healthcare systems

15 profitable health systems in Q1 FYI

About pharma

Amazon Can’t Shed Supplement Label Deception Consumer Class Suit: Amazon.com Services LLC failed to shake off a proposed class action alleging the e-commerce marketplace misled consumers into thinking supplements they bought on the site had therapeutic value and that the marketing claims were reviewed by the Food and Drug Administration. 

About healthcare IT

Joint Commission to create guidelines on AI’s use in healthcare: The Joint Commission has partnered with the Coalition for Health AI to establish and implement evidence-based guidance on the use of artificial intelligence in healthcare operations.
The first set of guidelines and best practices is slated to be released in the fall… 

About healthcare personnel

Relocation Post-Dobbs Among Clinicians Providing Abortions: This survey study found that after Dobbs, 42% of survey respondents who provided abortions in states banning abortion relocated to another state. Almost all clinicians who relocated from any policy context relocated to states not banning abortion. We document practice relocation rates vastly exceeding those of obstetrician-gynecologists from 2005 to 2015, and among obstetrician-gynecologists post-Dobbs…Given that most study respondents provided both abortion and nonabortion health care, these accelerated relocations have implications for abortion access and for the broader maternal health workforce, exacerbating health care deserts and outcome disparities.

53% of benefit managers know their wellness programs are failing employees: Ultimately, well-being initiatives will only have an impact when they are employee-centered, culturally supported and strategically integrated into the broader benefits ecosystem. As companies grapple with rising healthcare costs and evolving employee expectations, it's no longer enough to offer wellness as an add-on. It must be a pillar of the employee experience. 
Comment: The entire article is worth reading. Implementing employee heath programs without understanding what is being addressed and how individuals will adopt them is bound to fail.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

Strata Performance Trends Report- Market Insights from Q1 2025: The following report combines financial, operational, and claims data from hospitals, health systems, and other healthcare organizations across the country. Key findings include:
—Medical supply and drug expenses saw steady growth over the past two years, and that growth could accelerate due to the impacts of tariffs on imports.
—U.S. health systems saw growth in charity and bad debt deductions in recent years, including a more than 20% increase in charity deductions from Q1 2023 to Q1 2025.
—Medicaid accounts for more than 12% of revenue for most hospitals nationwide, with percentages ranging from 11.1% for hospitals in the Midwest to 14.4% for those in the West.
—Operating margins for U.S. health systems narrowed slightly to 0.9% in March, falling below 1% for the first time in 15 months after holding steady at 1% for both January and February.
—Patient demand was up nationwide across most metrics in March, following decreases in February, as growth in outpatient visits outpaced inpatient admissions. 

About pharma

Polypill Approved for Hypertension, Including as Initial Therapy: The FDA approved a polypill containing telmisartan, amlodipine, and indapamide, known as Widaplik, for the treatment of hypertension in adults, including as initial treatment.
This marks the first time that a triple combination medication has been indicated for initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals, manufacturer George Medicines noted in their announcement of the approvalopens in a new tab or window.
Initial monotherapy has historically been the default for hypertension. However, this often leads to suboptimal results, due to treatment inertia. 
Comment: PBMs typically do not approve such combinations as first or second line therapies. Physicians who want to use this pill will face push-back. 

About the public’s health

Firearm Laws and Pediatric Mortality in the US: Excess mortality analysis found that a group of states with the most permissive firearm laws after 2010 experienced more than 6029 firearm deaths in children and adolescents aged 0 to 17 years between 2011 and 2023 and 1424 excess firearm deaths in a group of states with permissive laws. In the most permissive states, the largest increase occurred in the non-Hispanic Black pediatric population; among all states, 4 states had statistical decreases in pediatric firearm mortality during the study period, all of which were in states with strict firearm policies. 

About healthcare personnel

New Oregon law sets nation’s strictest limits on corporate control of medical practices: State law mandates that physicians hold at least a 51% stake in most medical practices, but supporters of the new legislation say that companies have taken advantage of a loophole by employing their own physicians and putting their names down as clinic owners, according to the report. 
The legislation limits the control companies can have in a clinic’s operations and also bans noncompete agreements that prohibit physicians from taking a position at a different practice, the report said. The bill does not take effect immediately and has a three-year adjustment period for facilities to comply with the new restrictions. 
Hospitals, tribal health facilities, behavioral health programs and crisis lines are exempted from the legislation, according to the report. 

States ranked by share of healthcare workers FYI

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

RFK Jr. fires all 17 members of CDC's vaccine committee: Health and Human Services Secretary Robert F. Kennedy Jr. on Monday fired the 17 sitting members of the Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices (ACIP), claiming that removing all doctors and public health experts on the panel will restore public trust. 
According to Kennedy, each member was appointed by the Biden administration as part of a "concerted effort to lock in public health ideology" and to limit the Trump administration from taking "the proper actions to restore public trust in vaccines."
ACIP members usually serve four-year terms. Because 13 appointees took their seats in 2024, without the complete ouster, the committee would not have had a Kennedy-selected majority until 2028. 
"A clean sweep is necessary to reestablish public confidence in vaccine science," Kennedy said in the HHS release. 

RFK Jr.’s chronic disease agency would eliminate or reduce funding for some prevention programs: Budget documents released by the Trump administration Friday provide the first clear indication of the priorities of a proposed new agency focused on preventing chronic disease. 
The Administration for a Healthy America would absorb multiple federal agencies and existing programs, but the documents indicate that numerous initiatives axed from the Centers for Disease Control and Prevention through a reduction in force (RIF) in April will be resurrected with reduced funding — or not at all. 

NIH walks back ban on new grants for universities with DEI programs or Israel boycotts: The National Institutes of Health has, for now, walked back a policy requiring universities and other research institutes to certify that they do not have unlawful diversity, equity, and inclusion programs or boycotts of Israel in order to receive research dollars. 
The rule, which was initially posted in April, was seen as the next stage of using research funds as leverage against private universities and efforts to increase diversity in the sciences. It is unclear what prompted the rescission of the policy, which is effective immediately. But the notice published on Monday says, “NIH is awaiting further Federal-wide guidance and will provide a future update to the extramural community.”  

About health insurance/insurers

Medicare Advantage Plan Disenrollment: Beneficiaries Cite Access, Cost, And Quality Among Reasons For Leaving: Enrollees’ self-reported inability to access and receive high-quality care, more than perceived burdens of out-of-pocket costs, was associated with MA plan disenrollment, as was an objective measure of plan generosity. Difficulty accessing needed medical care was more strongly associated with MA-to–traditional Medicare exits than MA-to-MA plan switching. Dissatisfaction with access, cost, and quality was much more common for enrollees in poor health. These findings renew concerns about access to high-quality care for high-risk and other MA enrollees. 

Medicare Advantage Denies 17 Percent Of Initial Claims; Most Denials Are Reversed, But Provider Payouts Dip 7 Percent:Employing medical claims data from multiple MA plans, covering 30 percent of the entire MA market in 2019, our study found claim denial rates of 17 percent as a share of initial claim submissions. We also found that 57 percent of all claim denials were ultimately overturned. We calculated that denials resulted in a 7 percent net reduction in provider MA revenue, based on the dollar-weighted share of claim denials that were not overturned. However, the indirect impact of denials could be even greater than this direct effect that we measured.

Medicare Advantage Compliance Audit of Specific Diagnosis Codes That Coventry Health and Life Insurance Company [from the HHS OIG]:
-For the 10 high-risk groups covered by our audit, most of Coventry’s submissions of the selected diagnosis codes to CMS for use in CMS’s risk adjustment program did not comply with Federal requirements.
- For 249 of 300 sampled enrollee-years, the diagnosis codes that Coventry submitted to CMS were not supported by medical records and resulted in $752,587 in net overpayments. On the basis of our sample results, we estimated that Coventry received at least $6.9 million in net overpayments for 2018 and 2019.
-As demonstrated by the errors we identified, Coventry’s policies and procedures to prevent, detect, and correct noncompliance with CMS’s program requirements, as mandated by Federal regulations, could be improved.
Recommendations are in the report.

About hospitals and healthcare systems

National Hospital Flash Report: April 2025 Data Key Takeaways
1. Hospital financial performance improved between January and April.
On a year-to-date basis, hospital performance in the first four months of 2025 compared favorably to the same time period in 2024.
2. Average length of stay decreased and adjusted discharges per calendar day increased compared to the prior year period. This reflects improved patient throughput and a higher demand for hospital services.
3. Measures of patient volume showed improvement. Inpatient revenue, discharges, ED visits and operating room minutes all increased compared to the prior year period.  

About pharma

FDA Approved — And Ineffective: This investigation found that from 2013 through 2022:

  • Seventy-three percent of drugs approved by the FDA did not meet the agency’s four foundational standards required to show they work as expected. 

  • More than half of drug approvals were based on preliminary data rather than sound evidence that patients had fewer symptoms, improved function, or lived longer. 

  • Fifty-five of the 429 drugs approved met only one of the four standards needed to show that a drug is safe and effective; 39 drugs met none of them.

Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trials:Merck & Co. is a step closer to bringing the first oral PCSK9 inhibitor to market. On Monday, the company announced that its experimental pill, enlicitide decanoate (formerly MK-0616), hit its main goals in two Phase III trials, significantly lowering LDL cholesterol with a safety profile comparable to placebo and existing oral treatments. 
Comment: This oral form could significantly lower ther price for patients who need this drug. Among other cost-lowering factors is saving a physician visit with a facility fee.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

HHS budget proposal cuts NCI funding by 37%: The Trump administration has proposed allocating $4.53 billion for the National Cancer Institute in fiscal year 2026, marking a 37.2% decrease from the $7.22 billion the NCI received in fiscal 2025. 
Cancer research organizations and advocacy groups have expressed concern over the budget proposal, citing the link federal funding has to breakthroughs in cancer research and treatment.   

About health insurance/insurers

Medicare negotiations underway to lower prices for next batch of drugs: Medicare is negotiating the prices of 15 drugs, including Novo Nordisk's Ozempic. The government has until Nov. 30 to announce the agreed-upon Medicare prices. The lower prices would go into effect in January 2027.

CEO of healthcare software company convicted for role in $1B fraud scheme: The CEO of a healthcare software company was convicted by a federal jury for his role in operating a platform that generated fraudulent physicians’ orders to defraud Medicare and other payers out of more than $1 billion.
Gary Cox, 79, of Maricopa County, Ariz., was the CEO of Power Mobility Doctor Rx (DMERx), an internet-based platform that generated fraudulent orders for unnecessary orthotic braces, pain creams and other items, according to a June 3 Justice Department news release.

UnitedHealth Retail Traders Turn Bearish After Leaked Memo Shows Investor-Appeasing Steps Ahead Of Shareholder Meeting: Retail sentiment around UnitedHealth Group turned cautious after the company reportedly prepared a confidential internal memo ahead of its June 2 shareholder meeting, to coordinate responses aimed at allaying shareholder concerns about its business practices and reassure them about a return to growth and profitability, according to STAT…
The document appears to respond to a lawsuit alleging the company hid anticonsumer practices, including unethical claims denials that boosted profits.

About pharma

Lilly expands Welldoc partnership with new app for Zepbound and Mounjaro users: Lilly is deepening its partnership with digital health company Welldoc to launch a new app aimed at supporting patients taking its dual GIP/GLP-1 agonist, tirzepatide, in managing their cardiometabolic health.
The app includes features such as reminders, device integration, health data tracking and medication logging for the drug, which is marketed as Zepbound for weight-loss and Mounjaro to treat diabetes.  

About the public’s health

Vaccines could slash antibiotic use by 2.5B doses annually: Report: Vaccines have the potential to reduce global antibiotic use by 2.5 billion doses a year, according to a report from Wellcome Trust, which underscores their role in curbing antimicrobial resistance.  

Alcohol: Is Any Amount Safe for Health?: Although some studies have suggested such a benefit, those that better accounted for confounders have not

.Lead, arsenic found in popular rice brands: Study: A study conducted by Healthy Babies, Bright Future found that out of 145 rice samples nationwide, 100% of them contained arsenic. According to the organization, more than one in four exceeded the FDA’s action level for infant cereal…
Overall, the report found four toxic metals in these rice products: Arsenic, cadmium, lead and mercury.


About healthcare IT

Artificial intelligence vs human clinicians: a comparative analysis of complex medical query handling across the USA and Australia: The results show that AI-generated responses were generally more accurate and professional than human responses, suggesting potential benefits like increased efficiency, lower costs and enhanced patient satisfaction. However, significant concerns such as AI’s lack of emotional depth, data bias and the risk of displacing human clinicians must be addressed to fully utilize AI in clinical settings.  

About healthcare finance

23andMe to restart auction after former CEO wins challenge to Regeneron bid: 23andMe will hold another auction for its assets after former chief executive officer Anne Wojcicki successfully challenged the outcome of an earlier bidding round that was won by Regeneron Pharmaceuticals. The auction comes after the human genetics firm filed for Chapter 11 bankruptcy protection in March amid a downturn in its fortunes, including a previous hacking incident that has led to a class-action lawsuit.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

Trump Administration Revokes Federal Guidance Protecting Emergency Abortions: The Trump administration announced on Tuesday that it would revoke guidance to the nation's hospitals that directed them to provide emergency abortions to women when they are necessary to stabilize their medical condition.  

About health insurance/insurers

10.9 million projected to lose insurance in 2034 from ‘big, beautiful’ bill: The Congressional Budget Office estimates 10.9 million people will lose health insurance under President Donald Trump‘s One Big Beautiful Bill Act, including 1.4 million who are in the country without legal status in state-funded programs.
The office’s analysis also found that the bill cuts taxes by $3.75 trillion but increase federal deficits by $2.4 trillion over the next decade.

Medicare Plan Switching Among Beneficiaries With and Without a History of Cancer: In this cohort study of 2852 older adults, 31.52% without a history of cancer and 29.61% with a history of cancer switched Medicare coverage in the 2 years following initial plan selection. Initial choice of Medicare Advantage or traditional Medicare plus supplemental coverage was associated with a low likelihood of plan switching among respondents with and without a history of cancer. 

About the public’s health

The role of masks and respirators in preventing respiratory infections in healthcare and community settings: In summary, extensive evidence generated during the covid-19 pandemic confirms the superiority of respirators and supports the use of masks and respirators in the community during periods of high epidemic activity. Some gaps in research remain, including economic analyses, research in special population groups for whom masking is challenging, and research on countering disinformation.

Single Shot Against Both Influenza and COVID-19 Shows Promise in Phase 3 Trial: A novel multicomponent messenger RNA (mRNA) vaccine, mRNA-1083, demonstrated noninferiority to standard influenza and COVID-19 vaccines in adults aged 50 years or older, eliciting higher immune responses against most influenza strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata) and SARS-CoV-2 (Omicron XBB.1.5), according to a pivotal phase 3 study.
Comment: The problem is that HHS pulled funding from Moderna to create such a vaccine. 

Hypertension, Diabetes, and High Cholesterol Awareness Among US Adults: The proportion of US adults who were unaware of having hypertension increased significantly over the study period, particularly in young adults and women, while diabetes and high cholesterol level unawareness remained stable. By the 2021 to 2023 cycle, approximately 1 in 6 adults with hypertension and 3 in 10 with diabetes were unaware of their condition.

Study Supports Lowering Colon Cancer Screening Age: Key Takeaways

  • A single-center study supported recommendations to lower the colorectal cancer screening age from 50 to 45.

  • Screening colonoscopy outcomes were slightly less frequent in people ages 45-49 versus 50-54.

  • Only the risk of any adenoma was significantly lower in the younger age group.

About health technology

FDA will not appeal court decision striking down lab-developed test rule: The FDA has opted to not appeal a federal court decision that struck down the agency’s rule to regulate laboratory-developed tests as medical devices.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

2025 Milliman Medical Index: Healthcare costs for the average person increased 6.7%, from $7,378 in 2024 to $7,871 in 2025. Outpatient facility care and pharmacy are the primary drivers of this increase, with pharmacy costs rising 9.7% and outpatient facility care costs rising 8.5%. Together, these service categories contributed to 69% of the year-over-year cost increase for the average person.  

About Covid-19

CDC tweaks — but does not remove — COVID-19 vaccine recommendation for kids: Rather than recommending routine COVID-19 vaccination for healthy children aged 6 months to 17 years, the CDC’s website now says that patients in this age group “may receive COVID-19 vaccination, informed by the clinical judgment of a health care provider and personal preference and circumstances.” A note at the top of the relevant page indicates that the update was made May 29. 

About the public’s health

Dietary Sugar Intake and Incident Type 2 Diabetes [T2D] Risk: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies: These findings suggest that dietary sugar consumed as a beverage (SSB [non-diet sugar-sweetened beverages] and fruit juice) is associated with incident T2D risk. The results do not support the common assumption that dietary sugar (i.e., total sugar and sucrose), irrespective of type and amount, is consistently associated with increased T2D risk.

About healthcare IT

HHS names new national coordinator for health IT: Thomas Keane, MD, has been appointed assistant secretary for technology policy and the ninth national coordinator for health information technology at the Department of Health and Human Services.
This role, according to Politico, is responsible for drafting regulations for EHRs and helps shape the department’s data, technology and AI strategies.
Dr. Keane, according to HHS’ website, previously served within the Office of the Assistant Secretary for Technology Policy and was a senior advisor to the deputy secretary of HHS. 

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

23andMe founder says Fortune 500 company backs new buyout offer: The founder of 23andMe has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, saying she has the fresh financial backing of a Fortune 500 company. Anne Wojcicki said in court filings on Saturday that she has secured the support of a “Fortune 500 company with a current market capitalisation of more than $400bn and $17bn of cash on hand”.  Last month, 23andMe announced that the upstate New York-based biotech company Regeneron had won the bidding for the company with a $256mn all-cash deal. In her court papers, Wojcicki alleged that the debtor and its advisers had unfairly tilted the auction to Regeneron, a claim the company denied in its own court filings. 

HHS faces $31B cuts in proposed FY ’26 budget: 6 notes A good review of the proposed changes. Hint: most have nothing to do with withdrawal of DEI activities.

About Covid-19

RFK Jr. Says Healthy Pregnant Women Don’t Need Covid Boosters. What the Science Says. Read this article! Despite what the governmental “experts” are saying, the actual science contradicts them.

FDA approves Moderna’s new lower-dose COVID-19 vaccine: The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company’s existing shot, but a second option.
The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. 

About health insurance/insurers

Medicare Advantage Plan Disenrollment: Beneficiaries Cite Access, Cost, And Quality Among Reasons For Leaving: Enrollees’ self-reported inability to access and receive high-quality care, more than perceived burdens of out-of-pocket costs, was associated with MA plan disenrollment, as was an objective measure of plan generosity. Difficulty accessing needed medical care was more strongly associated with MA-to–traditional Medicare exits than MA-to-MA plan switching. Dissatisfaction with access, cost, and quality was much more common for enrollees in poor health. These findings renew concerns about access to high-quality care for high-risk and other MA enrollees.

Medicare Advantage Denies 17 Percent Of Initial Claims; Most Denials Are Reversed, But Provider Payouts Dip 7 Percent:[Using data from] 2019, our study found claim denial rates of 17 percent as a share of initial claim submissions. We also found that 57 percent of all claim denials were ultimately overturned. We calculated that denials resulted in a 7 percent net reduction in provider MA revenue, based on the dollar-weighted share of claim denials that were not overturned. However, the indirect impact of denials could be even greater than this direct effect that we measured. This article points to the important role that claim denials play in reducing MA spending and in driving outcome differences between MA and traditional Medicare. However, our analysis did not weigh the cost-saving benefits of claim denials against potential downsides.

Blue Shield of California posts $103M profit in 2024: Blue Shield of California reported a net income of $103 million in 2024, down more than 20% from $130 million in 2023.
In 2024, the company’s total revenue was $27.4 billion, up 8.2% year over year.
The company’s operating expenses rose more than 8% to $27.3 billion in 2024.

Exclusive: HHS watchdog finds more than $16B in health savings: The report was sent to Congress late Friday.
By the numbers:
—The HHS Office of Inspector General identified $16.6 billion in real and potential savings from October 2024 through March of this year.
—The office's investigations identified $3.5 billion in funds due back to the federal government, and its audits found another $451 million that the government will recoup.
—More than $12 billion in potential cost savings were identified if HHS makes recommended policy changes. The office issued 165 recommendations over the six months. 

About hospitals and healthcare systems

Advocate Health’s operating income up 217% in Q1: Charlotte, N.C.-based Advocate Health recorded an operating income of $329.1 million (3.6% operating margin) in the first quarter of 2025, up from $103.7 million (1.3% margin) during the same period last year, according to its May 30 financial report. 

About pharma

Sanofi to buy Blueprint Medicines in deal worth more than $9 billion: Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company. 

FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People [An FDA release]: Built within a high-security GovCloud environment, Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff.

Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23: With data on 146 oral-solid drugs experiencing first generic entry during the period 2016–23, we found evidence for both positive and negative effects of authorized generics on competition. On-invoice prices that pharmacies paid for new generics were 13–18 percent lower when an authorized generic was available. However, authorized generic launches, which were once common, declined markedly in more recent years, which may be partly explained by no-authorized-generic agreements in brand-generic patent litigation settlements. Curtailing these agreements could greatly benefit drug purchasers. 

About health technology

Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer: This prospective, population-based, observational study enrolled 48 995 participants aged 45 to 85 years at average risk of colorectal cancer. In a cohort of 27 010 evaluable participants, the blood test demonstrated 79.2% sensitivity for colorectal cancer and 91.5% specificity for advanced colorectal neoplasia using colonoscopy as the reference standard.
Comment: This test is not yet available but is getting a lot of attention in the public press. Please see the editorial comment below:
Blood-Based Colorectal Cancer ScreeningThe Illusion of Simplicity and the Cancer Prevention Paradox: …However, the illusion of simplicity is deceptive: the new test may paradoxically result in inferior outcomes if substituted for currently recommended tests or if follow-up colonoscopy is not completed in those with abnormal results. A blood test could be very effective if detection of early-stage cancer and advanced cancer precursors can be improved, and if individuals with an abnormal test finding are successfully navigated to colonoscopy. We believe that these should be the goals for future blood tests. But until such time, clinicians should educate their patients about the effectiveness of colonoscopy and stool-based screening, and should reserve offers of cell-free DNA blood tests for those who clearly refuse these strategies.

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

White House to fix ‘formatting errors’ in RFK Jr. ‘MAHA Report’: The White House on Thursday said it will fix errors in its “Make America Healthy Again,” or MAHA, report after a news outlet’s investigation found that it cited sources that don’t exist. The report, released last week to much fanfare by the administration, cited hundreds of studies to purportedly find the root causes of chronic diseases. Health and Human Services Secretary Robert F. Kennedy Jr. called the report a “milestone.”
But an examination by the news organization NOTUS found that some of those studies did not actually exist.  

About Covid-19

Contradicting RFK Jr., CDC keeps recommending covid vaccine for kids: Coronavirus vaccines are still recommended for healthy children if their doctors approve, according to updated immunization schedules published late Thursday by the Centers for Disease Control and Prevention, contradicting Health and Human Services Secretary Robert F. Kennedy Jr.’s announcement earlier this week

Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds: The findings are promising and suggest that, despite a drop in antibodies for mutated parts of the virus, vaccination offers ongoing protection from severe disease.

About health insurance/insurers

EMPLOYER HEALTH PLAN PERFORMANCE GAP EXPANDS, SAYS J.D. POWER:  KEY TAKEAWAYS:
The latest results from J.D. Power show a growing gap between high- and low- performing health plans in the U.S.
The best performers — regional, Blue Cross Blue Shield, and provider-sponsored plans — are getting better while the worst performers — the large national carriers — are getting worse.
Member experience has become a competitive differentiator — something for all carriers to keep in mind as employers make benefit decisions. 

About hospitals and healthcare systems

13 health systems with credit rating upgrades FYI

4 new health systems launched in 2025 FYI

About the public’s health

Projected Outcomes of Removing Fluoride From US Public Water Systems:This cost-effectiveness analysis using data for 8484 children (mean age, 9.6 years) from the US National Health and Nutrition Examination Survey for 2013 to 2016 found that elimination of fluoride would be associated with an increase in tooth decay of 7.5 percentage points and cost approximately $9.8 billion over 5 years.  

About healthcare personnel

Physician Practice Benchmark Survey Among the findings: Forty-two percent of physicians were in private practice in 2024, an 18 percentage point drop since 2012 (our first year of the Benchmark Survey)…An additional 7.7 percent of physicians (data not shown) indicated that they or another physician had an ownership stake in their practice but identified their practice as owned by a hospital, private equity group, or insurer…

Today's News and Commentary

Read today’s Kaiser Health News

In other news:

About Covid-19

A new variant of COVID-19 may be driving up cases in some parts of the world, WHO says: COVID-19 cases are rising again as a new variant begins to circulate in some parts of the world. The World Health Organization said Wednesday the rise in cases is primarily in the eastern Mediterranean, Southeast Asia and western Pacific regions.
Airport screening in the United States has detected the new variant in travelers arriving from those regions to destinations in California, Washington state, Virginia and New York.
The new variant is called NB.1.8.1. It arrives as the United States’ official stance on COVID-19 vaccination is changing. On Tuesday, Health Secretary Robert F. Kennedy Jr. announced that COVID-19 shots are no longer recommended for healthy children and pregnant women — a move immediately questioned by several public health experts.

About health insurance/insurers

States providing Medicaid coverage to undocumented immigrants could face $92B in penalties: States that extend Medicaid coverage to individuals without legal status will receive fewer federal Medicaid dollars if budget legislation passed by the House of Representatives is finalized, according to KFF
The legislation would reduce federal Medicaid funding matches to 80% instead of 90% for states that extend coverage to individuals regardless of immigration status. Currently, 14 states and the District of Columbia provide Medicaid coverage to undocumented children, and seven states extend coverage to undocumented adults. 

The top-ranked commercial health plans for member experience | 2025 FYI

Healthcare billing fraud: 10 recent cases  Note not only the type of fraud but that they involved federal programs.

About pharma

7 top pharmas posted revenue declines in Q1. The common thread? All are US firms FYI

About the public’s health

Moderna reports early immunogenicity data for bird flu jab as HHS pulls funding: Moderna is facing another setback from the vaccine-sceptical Trump administration, with the company disclosing Wednesday that the Department of Health and Human Services (HHS) has cancelled over $760 million in funding to develop vaccines for pre-pandemic influenzas — including bird flu. 
"After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable," remarked HHS Communications Director Andrew Nixon. "The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public."
The announcement came in conjunction with an interim data readout from Moderna's 300-person Phase I/II trial of its H5 avian influenza vaccine, mRNA-1018. 
More than 97% of participants who received two doses of the experimental vaccine had haemagglutination inhibition (HAI) antibody titres ≥1:40 — the level considered to be protective — at three weeks after the second vaccination. About 2% of individuals had protective levels of HAI antibodies at baseline. 
In addition, mRNA-1018 was generally well-tolerated, with most adverse reactions being either Grade 1 or 2, and no dose-limiting tolerability concerns. Moderna plans to present additional data at an upcoming scientific meeting.   
Comment: Another HHS political pronouncement masquerading as scientifically reasoned.